Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PepGen Inc. ( (PEPG) ) has provided an announcement.
On March 30, 2026, PepGen reported topline data from the lowest 5 mg/kg multiple ascending dose cohort of its Phase 2 FREEDOM2-DM1 trial of PGN-EDODM1 in myotonic dystrophy type 1, showing the drug was generally well tolerated with only mild or moderate adverse events and no serious events or treatment-related discontinuations. The cohort demonstrated modest mean splicing correction of 7.3% versus 6.8% on placebo, which rose to 22.9% when an outlier was excluded, along with positive trends in vHOT but no meaningful gains in 10-meter walk/run or handgrip strength, while PepGen continues dosing the 10 mg/kg cohort, expects data in the second half of 2026, and indicates it has cash to fund operations into the second half of 2027.
The most recent analyst rating on (PEPG) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.
Spark’s Take on PEPG Stock
According to Spark, TipRanks’ AI Analyst, PEPG is a Neutral.
The score is primarily held down by weak financial performance (no revenue, large ongoing losses and heavy cash burn). Technicals are mixed and not signaling strong momentum, valuation is constrained by losses and no dividend support, and corporate events add meaningful regulatory risk due to the FDA partial clinical hold despite some positive pipeline updates and stated cash runway.
To see Spark’s full report on PEPG stock, click here.
More about PepGen Inc.
PepGen Inc. is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. The company’s Enhanced Delivery Oligonucleotide platform uses cell-penetrating peptides to improve uptake and activity of conjugated oligonucleotide drugs, supporting a pipeline targeting the root causes of serious genetic conditions.
Average Trading Volume: 724,142
Technical Sentiment Signal: Hold
Current Market Cap: $312.4M
Find detailed analytics on PEPG stock on TipRanks’ Stock Analysis page.